The poor execution of a Phase III trial in Lyme disease has set back plans to submit vaccine candidate VLA15 for regulatory approval in the USA.
Developers Valneva (Nasdaq: VALN) and Pfizer (NYSE: PFE) disclosed in February that they would have to withdraw some participants from the VALOR study, after violations of clinical trial good practice were discovered.
The trial is being run by contract research organization (CRO) Care Access. In its quarterly results statement, Valneva has now revealed that the setback will delay regulatory submissions until 2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze